Jingze Biopharmaceutical

Jingze Biopharmaceutical is a clinical-stage biotechnology company headquartered in Hefei, China, specializing in the development of recombinant biologic drugs for assisted reproduction and ophthalmology. Founded in 2014, the company utilizes a synthetic biology platform to create high-barrier biosimilars and innovative biologics intended to replace animal-derived or biochemically extracted products. Its lead product, JZB30 (recombinant human follicle-stimulating hormone), received NDA approval in China in 2025 for the treatment of infertility and ovulation induction. The company's pipeline also includes JZB05, an aflibercept biosimilar in Phase 3 trials for retinal diseases, and JZB32, a recombinant truncated plasmin for polypoidal choroidal vasculopathy. Jingze maintains integrated capabilities spanning R&D, pilot transformation, and commercial-scale GMP manufacturing across its facilities in Hefei, Shanghai, and Chengdu. The company has attracted significant investment from venture capital firms and filed for an IPO on the Hong Kong Stock Exchange in 2025.